Hyperliquid Strategies Inc (NASDAQ:PURR – Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 9,440,520 shares were traded during mid-day trading, a decline of 1% from the previous session’s volume of 9,516,014 shares.The stock last traded at $13.3620 and had previously closed at $11.56.
Key Stories Impacting Hyperliquid Strategies
Here are the key news stories impacting Hyperliquid Strategies this week:
- Positive Sentiment: Hyperliquid Strategies reported fiscal 2026 net income of approximately $305.5 million and highlighted major operational progress, including more than doubling its HYPE treasury, launching a large network validator and completing its exit from legacy biotech operations. Hyperliquid Strategies Inc Reports Financial Results for the Fiscal Year Ended June 30, 2026
- Positive Sentiment: The company disclosed a HYPE position valued at roughly $1.9 billion, with its treasury reportedly reaching about 29.3 million tokens. Investors appear to be treating the treasury as a direct way to gain exposure to the Hyperliquid ecosystem. Hyperliquid Strategies Shares Rise After Reporting $1.9B HYPE Position
- Positive Sentiment: HYPE reached a record price near $84.80, increasing the reported value of Hyperliquid Strategies’ token holdings and supporting the stock’s momentum. Hyperliquid HYPE Surges to Record $84.80
- Neutral Sentiment: Chardan Capital reaffirmed a Buy rating and raised its outlook, but its reported $9.75 price target is below the stock’s recent trading level, suggesting analysts may be lagging the rally or see limited near-term upside. Why Is Hyperliquid Strategies Stock Up on Friday?
- Negative Sentiment: Technical commentary warns that the HYPE rally may be becoming stretched, while the company’s results and valuation remain highly sensitive to cryptocurrency prices. A reversal in HYPE could reduce the value of PURR’s treasury and pressure the shares. Hyperliquid Price Forecast
Analyst Ratings Changes
Several brokerages have issued reports on PURR. Chardan Capital raised their price objective on Hyperliquid Strategies from $9.75 to $17.00 and gave the stock a “buy” rating in a report on Friday. Cantor Fitzgerald set a $22.60 target price on Hyperliquid Strategies and gave the company an “overweight” rating in a report on Thursday. Finally, Weiss Ratings raised Hyperliquid Strategies from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.53.
Hyperliquid Strategies Trading Down 9.5%
The business’s fifty day moving average price is $7.86 and its 200 day moving average price is $6.88. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of -1.58 and a beta of 1.71.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the company. State of Wyoming purchased a new position in Hyperliquid Strategies during the second quarter worth about $46,000. Shepherd Financial Partners LLC purchased a new stake in Hyperliquid Strategies in the 2nd quarter valued at approximately $79,000. Boothbay Fund Management LLC acquired a new position in Hyperliquid Strategies during the 4th quarter worth approximately $40,000. Lotus Technology Management LP acquired a new position in Hyperliquid Strategies during the 2nd quarter worth approximately $93,000. Finally, XTX Topco Ltd purchased a new position in shares of Hyperliquid Strategies during the 4th quarter worth approximately $48,000. 9.45% of the stock is currently owned by institutional investors and hedge funds.
About Hyperliquid Strategies
Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc, is based in NEW YORK.
Featured Stories
- Five stocks we like better than Hyperliquid Strategies
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Hyperliquid Strategies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperliquid Strategies and related companies with MarketBeat.com's FREE daily email newsletter.
